Literature DB >> 26074687

Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus.

Magnus Halland1, David Katzka1, Prasad G Iyer1.   

Abstract

The burden of illness from esophageal adenocarcinoma continues to rise in the Western world, and overall prognosis is poor. Given that Barrett's esophagus (BE), a metaplastic change in the esophageal lining is a known cancer precursor, an opportunity to decrease disease development by screening and surveillance might exist. This review examines recent updates in the pathogenesis of BE and comprehensively discusses known risk factors. Diagnostic definitions and challenges are outlined, coupled with an in-depth review of management. Current challenges and potential solutions related to screening and surveillance are discussed. The effectiveness of currently available endoscopic treatment techniques, particularly with regards to recurrence following successful endotherapy and potential chemopreventative agents are also highlighted. The field of BE is rapidly evolving and improved understanding of pathophysiology, combined with emerging methods for screening and surveillance offer hope for future disease burden reduction.

Entities:  

Keywords:  Barrett’s esophagus; Esophageal cancer; Esophagus; Gastroesophageal reflux disease

Mesh:

Substances:

Year:  2015        PMID: 26074687      PMCID: PMC4458759          DOI: 10.3748/wjg.v21.i21.6479

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  107 in total

1.  The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus.

Authors:  A P Thrift; N Pandeya; K J Smith; A C Green; P M Webb; D C Whiteman
Journal:  Aliment Pharmacol Ther       Date:  2011-10-03       Impact factor: 8.171

2.  Garlic, silver bullets, and surveillance upper endoscopy for Barrett's esophagus.

Authors:  Nicholas J Shaheen; Chin Hur
Journal:  Gastroenterology       Date:  2013-06-24       Impact factor: 22.682

3.  Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus.

Authors:  David I Fudman; Charles J Lightdale; John M Poneros; Gregory G Ginsberg; Gary W Falk; Maureen Demarshall; Milli Gupta; Prasad G Iyer; Lori Lutzke; Kenneth K Wang; Julian A Abrams
Journal:  Gastrointest Endosc       Date:  2014-02-22       Impact factor: 9.427

4.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

5.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

6.  A multibiomarker risk score helps predict risk for Barrett's esophagus.

Authors:  Aaron P Thrift; Jose M Garcia; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-19       Impact factor: 11.382

7.  Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.

Authors:  Tatiana Benaglia; Linda D Sharples; Rebecca C Fitzgerald; Georgios Lyratzopoulos
Journal:  Gastroenterology       Date:  2012-10-03       Impact factor: 22.682

Review 8.  Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Abha Goyal Singh; Preet Paul Singh; Mohammad Hassan Murad; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

9.  Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus.

Authors:  D A Katzka; D O Castell
Journal:  Am J Gastroenterol       Date:  1994-07       Impact factor: 10.864

10.  Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study.

Authors:  Sudarshan R Kadri; Pierre Lao-Sirieix; Maria O'Donovan; Irene Debiram; Madhumita Das; Jane M Blazeby; Jon Emery; Alex Boussioutas; Helen Morris; Fiona M Walter; Paul Pharoah; Richard H Hardwick; Rebecca C Fitzgerald
Journal:  BMJ       Date:  2010-09-10
View more
  5 in total

Review 1.  Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?

Authors:  Fouad Otaki; Prasad G Iyer
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

Review 2.  The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis.

Authors:  Don Chamil Codipilly; Apoorva Krishna Chandar; Siddharth Singh; Sachin Wani; Nicholas J Shaheen; John M Inadomi; Amitabh Chak; Prasad G Iyer
Journal:  Gastroenterology       Date:  2018-02-16       Impact factor: 22.682

3.  WATS3D versus forceps biopsy in screening for Barrett's esophagus: experience in community endoscopy centers.

Authors:  Yasmine Hussein Agha; Sachin Srinivasan; Jeffrey Hyder; Chelsea Wuthnow; Ali Taleb; Nathan Tofteland; William Kilgore; William Salyers
Journal:  Ann Gastroenterol       Date:  2020-12-07

Review 4.  Esophageal cancer research today and tomorrow: Lessons from algae and other perspectives.

Authors:  Vladlena Tiasto; Valeriia Mikhailova; Valeriia Gulaia; Valeriia Vikhareva; Boris Zorin; Alexandra Kalitnik; Alexander Kagansky
Journal:  AIMS Genet       Date:  2018-03-07

5.  Clinical-morphological profiles of esophageal carcinoma's main types.

Authors:  Dan Cameniţă; Alin Dragoş Demetrian; Răzvan Mihail Pleşea; Manuela Ioana Tănasie-Vasile; Victor Dan Eugen Strâmbu; Valentin Titus Grigorean; Elena Ioniţă; Iancu Emil Pleşea; Augustin Marian Marincaş
Journal:  Rom J Morphol Embryol       Date:  2020 Apr-Jun       Impact factor: 1.033

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.